-3.18% for Eli Lilly stock — Volatility spikes amid bearish daily signals

-3.18% for Eli Lilly stock — Volatility spikes amid bearish daily signals
Eli Lilly drops 3.18% to $1,019

Eli Lilly and Company (LLY) is trading at $1,019.12 after a daily decline of 3.18%. The price is positioned below both its MA-20 ($1,036.33) and MA-50 ($1,053.10), yet remains well above the MA-200 ($874.42), indicating short- and medium-term bearish momentum against a still constructive long-term trend. Immediate resistance is defined by the Ichimoku Kijun at $1,053.79.

LLY price prediction
24H -0.34%
$1,427.44
48H -0.58%
$1,424.09
7D -1.23%
$1,414.72
1M 11.08%
$1,591.09
3M 33.84%
$1,917.01
6M 18.31%
$1,694.64
12M 42.73%
$2,044.39
Current price: $1,432.36 -12.4400 0.86%
Closed 11/16
Daily range 1428.22 Arrow from to Icon 1469.75
Weekly range 1409.03 Arrow from to Icon 1469.75
Loading...

Highlights

  • Eli Lilly commissioned the new LillyPod supercomputer with Nvidia on February 25, 2026, advancing its tech infrastructure to support growth.
  • Growth is driven by GLP-1 drugs Mounjaro and Zepbound, with Zepbound approved for weight loss and the current dividend policy maintained despite industry challenges.
  • LLY trades at $1,019.12, below MA-20 and MA-50 but above MA-200, with $1,015–$1,070 flagged as the key near-term trading corridor and $1,054 as immediate resistance.

GLP-1 drug-driven growth as new tech investments face market pressure

On February 25, 2026, Eli Lilly commissioned the new LillyPod supercomputer in partnership with Nvidia, expanding its technological infrastructure. The company also reported growth driven by its GLP-1 drugs, Mounjaro and Zepbound, with Zepbound approved for weight loss. Eli Lilly stated it will maintain its current dividend level while managing broader industry challenges, though price action has remained under broader selling pressure.

Momentum divergence as oscillators warn of overbought conditions

Momentum for LLY is mixed: the daily MACD signals a strong sell, and the ADX is neutral, highlighting weak directional conviction. While RSI is modestly bullish at 52.49, both the Stochastic RSI and Bull/Bear Power point to overbought levels, suggesting recent buyer dominance and potential for mean reversion. Today saw a slight gap up at the open, but prices slid towards session lows amid heightened intraday volatility with downside pressure. Conflicting momentum and oscillator signals reveal divergence between medium-term bullish indications and short-term caution, with key resistance at $1,053.79 and typical support levels at $1,015 and $874.42.

Upside potential as breakout risk contests consolidation bias

Over the next five trading days, LLY is likely to move within a volatility band of $1,015 to $1,070. Weekly momentum and trend indicators point to a greater than 80% probability of further price gains, while the baseline scenario sees consolidation within this corridor. A sustained breakout above $1,054 could open the way to $1,070, whereas a move below $1,015 would increase the risk of a deeper pullback toward long-term support.
Anton Kharitonov, expert at Traders Union, sees Eli Lilly facing a mixed setup after recent downside. He believes technical signals remain conflicted, with short-term caution reinforced by negative session momentum, despite a supportive long-term trend and positive news on product growth and technology investment. Price remains vulnerable unless it reclaims $1,054 resistance. "Until LLY can break above $1,054, my stance is cautious and I see a risk of further pullback in the near term."
Previously it was reported that Eli Lilly is trading slightly below its 20- and 50-day moving averages but remains well above its 200-day, with short-term selling pressure weighing on an otherwise bullish medium- and long-term trend. Momentum indicators are mixed, with bearish MACD and overbought signals on oscillators like Stoch RSI and BBP, while neutral RSI and ADX suggest a possible turning point amid elevated volatility and market caution.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.